免疫学
淋巴瘤
多发性骨髓瘤
细胞疗法
医学
癌症研究
疾病
肿瘤微环境
生物
免疫系统
干细胞
内科学
细胞生物学
作者
Aimee Merino,Joseph Maakaron,Veronika Bachanová
出处
期刊:Blood Reviews
[Elsevier]
日期:2023-07-01
卷期号:60: 101073-101073
被引量:10
标识
DOI:10.1016/j.blre.2023.101073
摘要
Natural Killer (NK) cells yield promise in therapy of hematologic malignancies. The clinical experience with adoptively transferred allogeneic NK cells over past two decades has revealed safety and minimal risk of CRS or ICANS. Unlike T cells which have to be genetically altered to avoid graft vs host disease (GVHD), HLA mismatched NK cells can be infused without GVHD risk. This makes them ideal for the development of off-the-shelf products. In this review we focus on NK biology relevant to the cancer therapy, the trajectory of NK therapeutics for leukemia, lymphoma, and myeloma; and advantages of the NK cell platform. We will also discuss novel methods to enhance NK cell targeting, persistence, and function in the tumor microenvironment. The future of NK cell therapy depends on novel strategies to realize these qualities.
科研通智能强力驱动
Strongly Powered by AbleSci AI